TrialAnnals of hematology2014

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.

Ulrike Proetel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.